Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma

14 Apr 2020

Abstract excerpt

PURPOSE: Circulating tumor DNA (ctDNA) has been used for disease monitoring in several types of cancer. The aim of our study was to investigate whether ctDNA can be used for response monitoring in neuroblastoma. METHODS: ). ctDNA results were compared with mRNA-based minimal residual disease (qPCR) in bone marrow (BM) and blood and clinical patient characteristics. RESULTS: ctDNA was detected at diagnosis in all...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer, Hypoxia, and Metabolism
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32923888
DOI: 10.1200/po.19.00261

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in NeuroblastomaPMID 32923888Read ↗

RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic markerSemantic proximity Read ↗

Evaluation of Minimal Residual Disease in Patients with NeuroblastomaSemantic proximity Read ↗

Circulating Methylated- DCR2 Gene in Serum as an Indicator of Prognosis and Therapeutic Efficacy in Patients with MYCN Nonamplified NeuroblastomaSemantic proximity Read ↗

Serial monitoring of circulating tumour DNA on clinical outcome in myelodysplastic syndromes and acute myeloid leukaemiaSemantic proximity Read ↗

Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual DiseaseSemantic proximity Read ↗

Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.Semantic proximity Read ↗

Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastomaSemantic proximity Read ↗

Exploiting Gene Expression Profiling to Identify Novel Minimal Residual Disease Markers of NeuroblastomaSemantic proximity Read ↗

5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with NeuroblastomaSemantic proximity Read ↗

Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes.Semantic proximity Read ↗

Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis.Semantic proximity Read ↗

Adrenergic and mesenchymal signatures are identifiable in cell-free DNA and correlate with metastatic disease burden in children with neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.